Deciphering the pharmacological mechanisms of *Chaenomeles Fructus* against rheumatoid arthritis by integrating network pharmacology and experimental validation

Mengjia Sun | Haijun Zhao | Yuecheng Liu | Yanni Ma | Zhenhua Tian | Huanjun Wang | Sheng Wei | Qingmei Guo | Zhengwei Gu | Haiqiang Jiang

1School of Pharmaceutical Sciences, Shandong University of Traditional Chinese Medicine, Jinan, China
2School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
3Shandong Academy of Traditional Chinese Medicine, Jinan, China
4Experiment Center, Shandong University of Traditional Chinese Medicine, Jinan, China
5Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan, China
6Shandong Provincial Key Laboratory of Traditional Chinese Medicine for Basic Research, Shandong University of Traditional Chinese Medicine, Jinan, China

**Abstract**

*Chaenomeles Fructus* is a plant that can be used for both food and medicine. Modern studies have shown that *Chaenomeles Fructus* has anti-inflammatory and immunosuppressive effects on arthritis. However, the mechanism of action of *Chaenomeles Fructus* on rheumatoid arthritis (RA) and its main active ingredients are still unclear. This study was aimed at devising an integrated strategy for investigating the bioactivity constituents and possible pharmacological mechanisms of *Chaenomeles Fructus* against RA. The components of *Chaenomeles Fructus* were analyzed using UPLC-Q-Exactive orbitrap MS techniques and applied to screen the active components of *Chaenomeles Fructus* according to their oral bioavailability and drug-likeness index. Then, we speculated on the potential molecular mechanisms of *Chaenomeles Fructus* against RA through a network pharmacology analysis. Finally, the potential molecular mechanisms of *Chaenomeles Fructus* against RA were validated in a complete Freund’s adjuvant (CFA)-induced RA rat model. We identified 48 components in *Chaenomeles Fructus* and screened seven bioactive ingredients. The results of the network pharmacology prediction and the experimental verification results were analyzed by Venn analysis, and the experimental results concluded that *Chaenomeles Fructus* mainly interferes with the inflammation of RA by inhibiting arachidonic acid metabolism and the MAPK signaling pathway. This study identified the ingredients of *Chaenomeles Fructus* by UPLC-Q-Exactive orbitrap MS and explained the possible mechanisms of...
1 | INTRODUCTION

*Chaenomeles Fructus*, the dry and near mature fruit of the Rosaceae plant *Chaenomeles speciosa* (Sweet) Nakai, dispels wind and dehumidification and can be used to prevent and treat rheumatism, cholera, dysentery, enteritis, beriberi, vitamin C deficiency, etc. (Hou, 2011; Hu et al., 2021; Jiangsu New Medical College, 1997; Qin et al., 2015; Zhang et al., 2018). Modern studies have shown that *Chaenomeles Fructus* has anti-inflammatory and immunosuppressive effects on arthritis (Gao, 2007; Hou, 2011; Hu et al., 2021; Zhang et al., 2018). Some of the main constituents in *Chaenomeles Fructus*, including oleanolic acid, betulinic acid, and ursolic acid, possess potential anti-inflammatory properties (Zhang et al., 2014). The anti-inflammatory effect of *Chaenomeles Fructus* is the holistic effect of the combination of its multiple components. However, the mechanism of action of *Chaenomeles Fructus* on RA and the main active ingredients are still unclear.

Rheumatoid arthritis (RA) is a chronic autoimmune joint disease characterized by inflammation of synovial tissue, which can cause cartilage and bone damage in addition to disability (Smolen et al., 2016). It affects approximately 1% of the population worldwide, and its current treatment strategies are costly (Silman & Pearson, 2002). Moreover, in such disorders, inflammation can further extend to damage other body organs than the joints, comprising the heart, lungs, eyes, and skin (Cojocaru et al., 2010). Currently, medications for the treatment of RA, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), have serious side effects, including cardiovascular diseases and hepatotoxicity, which limit their extensive clinical use (Chen et al., 2020). Given the side effects of existing therapies, such as limited efficacy, potential toxicity, and high cost, many countries have paid great attention to herbal therapy (Kuwana et al., 2018). For example, Tripterygium glycosides have anti-inflammatory and immunomodulatory effects and are considered to be the most effective medicinal plants for treating RA in China. However, the side effects and toxicity of Tripterygium glycosides cannot be ignored. Thus, it is necessary to find drugs with good curative effects and few side effects.

With the rise of systems biology, network pharmacology uses big data to visualize the connections of complex systems and to provide new ideas and approaches for the study of mechanisms in treating diseases (Wang et al., 2021). It uses a variety of analytical tools to extract relevant data from massive amounts of biological information and medicinal plant information to build disease gene or medicinal plant active ingredient–protein target interaction networks for data mining, thereby establishing the disease regulatory networks of medicinal plants and their formulas. The synergistic mechanisms of the complicated medicinal plant formulas can be elucidated in greater depth by combining the results from proteomics, transcriptomics, or metabolomics. For instance, in a recent study, the mechanisms of Shenyang Kangfu tablets in treating diabetic nephropathy were studied through network pharmacology combined with metabolomics (Wang et al., 2021).

This study, based on the scientific strategy of network pharmacology, aimed to systematically investigate the predicted therapeutic targets and biological signaling pathways of *Chaenomeles Fructus* against RA. In addition, we established a complete Freund’s adjuvant (CFA)-induced RA rat model for verification. A metabolomics method based on UPLC-Q-Exactive orbitrap MS was used to collect the serum metabolic profiles of rats and explore the metabolic changes that occurred after *Chaenomeles Fructus* treatment. The MAPK signaling pathway involved in MAPK3 targets was selected for validation in the current models. The specific experimental process is shown in Figure 1.

2 | MATERIALS AND METHODS

2.1 | Chemicals and reagents

The reference standards for oleanolic acid, betulinic acid, maslinic acid, quercetin, rutin, quercetin, hyperin, protocatechuic acid, chlorogenic acid, shikimic acid, gallic acid, caffeic acid, kojic acid, cinnamic acid, vanillic acid, benzoic acid, p-hydroxybenzoic acid, succinic acid, fumaric acid, and L-3-phenyl lactic acid were purchased from Minster Co., Ltd. (Chengdu, China). Acetonitrile, methanol, and formic acid (HPLC grade) were obtained from Fisher Company, USA. 10% chloral hydrate was purchased from Damao Chemical Reagent Factory Ltd. (Tianjin, China). Complete Freund’s adjuvant (CFA) was obtained from Sigma Aldrich (Milan, Italy); Tripterygium Glycosides (TG) were purchased from Meitong Pharmaceutical Co., Ltd. (Jiangsu, China). *Chaenomeles Fructus* was obtained from Anhui People’s Traditional Chinese Medicine Pieces Co., Ltd. (Anhui, China) and identified by Prof. Qingmei Guo, Shandong University of Traditional Chinese Medicine.
2.2 | UPLC-Q-Exactive Orbitrap MS for chemical characterization

2.2.1 | UPLC-Q-Exactive Orbitrap MS conditions

UPLC-Q-Exactive Orbitrap MS analysis was used for a comprehensive analysis of the constituents in *Chaenomeles Fructus* extract. The chromatography system was equipped with an autosampler, a diode-array detector, a column compartment, and two pumps. The chromatographic conditions were optimized, and a Halo C18 column (2.1 × 100 mm, 2.7 μm, AMT, USA) maintained at 40°C was finally chosen for separation of *Chaenomeles Fructus* alcohol extract. The mobile phase consisted of solvent A (0.05% formic acid in water) and solvent B (0.05% formic acid in acetonitrile). The following gradient program was used: 0–5 min 5% B, 5–15 min 5% B to 15% B, 15–17 min 15% B to 45% B, 17–40 min 45% B to 95% B, 40–40.1 min 95% B to 5% B, 40.1–45 min 5% B. The flow rate was set at 0.3 ml/min. The injection volume was 3.0 μl, and the sampler was set at 4°C.

Meanwhile, mass spectrometry detections were set as follows: capillary temperature 350°C; S-lens RF level 55.0; spray voltage 3.5 kV; sheath gas (N₂) flow rate 45 arb; auxiliary gas (N₂) flow rate 15 arb; mass spectrometry acquisition range 80–1200 m/z; and resolution 17,500. Data acquisition is done through Xcalibur 4.1 software operated in positive and negative ion mode.

2.2.2 | Sample preparation

The *Chaenomeles Fructus* was ground into powder, accurately weighed 0.5 g, dissolved in methanol with sonication for 30 min, and then use methanol to supplement the weight loss. The solution was further filtrated through 0.22 μm membrane for LC-MS/MS analysis.

2.2.3 | Preparation of standard solution

Precisely weigh 2.00 mg of the above-mentioned standard product and place it in a 10 ml volumetric flask. Dissolve to a fixed volume with methanol as the standard solution and store it at 4°C. The mixed solution of the standard was diluted 100 times with methanol and treated with ultrasound at room temperature for 30 min. Methanol was added to make up the weight loss and filtered through 0.22 μm membrane.

2.3 | Network pharmacology study

The construction of the network was mainly based on the overall prediction of the TCMSP (http://ibts.hkbu.edu.hk/lsp/tcmsp.php), Swiss TargetPrediction (http://www.swisstargetprediction.ch/), TTD (https://db.idrblab.org/ttd/), OMIM (http://omim.org/).
STRING (https://string-db.org/), and Metascape (http://metascape.org/) databases for the treatment of RA with Chaenomeles Fructus. The procedure for network construction was as follows: (1) Based on the qualitative identification results of mass spectrometry, compounds that met the requirements of oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 were extracted from the TCMSP database, and the potential active compounds were screened out. Their corresponding targets were queried in the TCMSP and Swiss TargetPrediction databases (Daina et al., 2019; Ru et al., 2014). (2) We collected gene targets for RA from two sources. The first source was the TTD (http://db.idrblab.net/tdt/) (Wang, Yu, et al., 2020). We used the keyword “rheumatoid arthritis” to search this database. The second source was the Online Mendelian Inheritance in Man (OMIM) database (www.omim.org/, updated on 28 February 2019) (Hamosh et al., 2005). (3) First, we intersected the obtained drug targets with the genes associated with disease and obtained a Venn diagram of the intersected gene symbols. These overlapping targets were further checked and retrieved into UniProt ID by using UniProt (https://www.uniprot.org/) (The UniProt Consortium, 2018). (4) The protein–protein interaction (PPI) analysis was performed by employing String (https://string-db.org/) (Szklarczyk et al., 2019) and visualized by Cytoscape 3.8.2 (Shannon, 2003). The action targets of Chaenomeles Fructus on RA ulcers were uploaded from the Metascape (http://metascape.org/) database, and the functions of biological process (BP), cellular component (CC), and molecular function (MF) were obtained by enrichment, and an enrichment analysis was carried out (Zhou, Yu, et al., 2019). Through the analysis of KEGG signaling pathways in the Metascape database, we comprehensively predicted the biological characteristics and regulatory pathways of Chaenomeles Fructus acting on RA targets. The calculation formula (RichFather = the number of genes belonging to this pathway in the target gene set/ the number of all genes in this pathway in the background gene set) was adopted, and the bubble chart was drawn (Li et al., 2020).

2.4 | Experimental validation

2.4.1 | Animals

Male Sprague–Dawley (SD) rats (weight, 160–200 g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd (Beijing, China; Certificate No. SCXK 2016–0006). All rats were housed in a specific pathogen-free (SPF) facility at a constant temperature of 23°±1°C with a relative humidity environment of 55%±5% and a standard 12h/12h (light/dark) cycle. Animals were allowed free access to water and fed a unified basic diet. Prior to the start of the experiment, the animals were maintained in hygienic conditions for at least a week to adapt to the environment. All animal welfare and experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the protocols used were approved by the Animal Ethics Committee of Shandong University of Traditional Chinese Medicine Laboratory Animal Center, Jinan, China.

2.4.2 | Animal experiments

Animals were randomly divided into six groups (11 rats/group). Each rat was injected with 0.1 ml CFA (10 mg/ml) both in and around the articular cavity, except for the control group. Treatment of rats began 1 day after induction. Group 1 included nonimmunized rats (control), and rats in Groups 2–6 included animals receiving the experimental drug. Group 2 included rats treated with intragastric saline administration (model). Group 3 included rats treated with intragastric Chaenomeles Fructus at 0.15 g/kg/day (low). Group 4 included rats treated with intragastric Chaenomeles Fructus at 0.30 g/kg/day (medium). Group 5 included rats treated with intragastric Chaenomeles Fructus at 0.60 g/kg/day (high). Group 6 included rats treated with intragastric TG at 0.009 g/kg/day (TG). Rats received administration for 3 weeks. After 24 h of the last administration, all animals were anesthetized with 1.5% pentobarbital sodium, and blood samples and synovial tissue were collected. Blood samples were drawn into the Eppendorf tubes, allowed to clot for 30 min, and then centrifuged (999 g, 4°C) for 15 min to obtain serum samples. The serum samples and synovial tissue were stored at −80°C until analysis.

2.4.3 | Measurement of paw swelling

Paw swelling was evaluated by measuring the diameters (mean of three readings) of both the injected and noninjected paws using a toe volume measuring instrument (Calvin Biotechnology Co., Ltd., China) before (Day 0) and after (hour 4, Day 7, Day 21) CFA immunization. The difference in the paw volumes after and before inflammation at certain time points indicated the paw swelling degree of rats at that time point (mL = volume of inflamed paw volume of noninflamed paw) (Zhou, Zhou, et al., 2019).

2.4.4 | Serum untargeted analysis by UPLC-Q-Exactive orbitrap MS

Preparation of serum samples

When the serum metabolites were analyzed, the serum samples were melted at 4°C. Serum samples (100 μl) and acetonitrile (400 μl) were mixed in a tube to remove proteins from the serum, including 2-chloro-L-phenylalanine (0.05 mg/ml, 15 μl) as an internal standard. The mixture was vortexed for 2 min, allowed to stand at 4°C for 10 min, and then centrifuged at 15,984 g for 20 min at 4°C. The supernatant (400 μl) was placed in a 2 ml EP tube, dried with nitrogen, and then redissolved by adding the initial mobile phase of 100 μl. The solution was centrifuged at 12,000 rpm for 5 min at 4°C, and 70 μl of the supernatant was injected into the column for LC-MS analysis.

LC-MS/MS conditions

Ultra-performance liquid chromatography–electrospray ionization tandem mass spectrometry (UPLC-ESI-MS) analysis was performed
using a hybrid Quadrupole-Orbitrap high-resolution mass spectrometer (Q-Exactive, QE) coupled with an Ultimate 3000 UPLC system (Thermo Fisher, USA). Data acquisition was performed by Xcalibur 4.1 software operated in positive mode. The sample vials were maintained at 10°C in a thermostatic autosampler. Chromatographic separation was achieved on a Halo C18 column (2.1 × 100 mm, 2.7 μm; AMT, USA) with the column temperature set at 45°C. A total of 5 μl of each sample was injected into the column. The mobile phase was composed of water (0.05% formic acid, A) mixed in gradient mode with acetonitrile (0.05% formic acid, B) at a flow rate of 0.3 ml/min. The elution gradient was optimized as follows: 0–1 min 2% B, 1–3 min 2% B to 20% B, 3–4 min 20% B, 4–7 min 20% B to 40% B, 7–9 min 40% B to 70% B, 9–15 min 70% B to 98% B, 15–17 min 98% B. Meanwhile, mass spectrometry detections were set as follows: capillary temperature 300°C; S-lens RF level 55.0; spray voltage 3.5 kV; sheath gas (N2) flow rate 45 arb; auxiliary gas (N2) flow rate 10 arb; mass spectrometry acquisition range 80–1300 m/z; resolution 70,000.

2.4.5 Western blot to detect the protein expression of ERK, JNK, P-ERK, and P-JNK

A protein extraction kit was used to extract the total protein from synovial tissue, and a BCA kit was used to detect the protein concentration of the sample. Each group took a sample solution containing the same total protein mass for electrophoresis, transferred the protein to a PVDF membrane, added 5% skimmed milk powder, and blocked for 2h at room temperature. The dilution multiples of rabbit ERK, JNK, P-ERK, and P-JNK primary antibodies were 1:1000, 1:1000, 1:1000, and 1:2000, respectively. The goat anti-rabbit secondary antibody was diluted at 1:5000, and the color was developed by enhanced chemiluminescence. The gel imaging system was used to take pictures, and the relative expression of each protein group was analyzed by ImageJ software.

2.5 Data processing and statistical analysis

Data were collected by using the Xcalibur data system that comes with the instrument. The acquired mass spectrometry data (.raw) were exported into Compound Discover (CD, Thermo Fisher, CA, USA) software for data analysis. CD software converts mass spectrometry data into metabolite information. These metabolic discoveries are achieved through a combination of online open databases and local databases, and MS/MS data of metabolites, which greatly improves the accuracy of metabolite identification. To find the differences between the groups, the data were imported into SIMCA-P13.0 software (Umetrics, Sweden) for principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA), using PLS-DA for supervised pattern recognition analysis of serum data. Through the CD software, the variables with p < .05 and VIP values >1 were screened as difference variables, and the metabolites with mzCloud matching higher than 70 were screened as potential biomarkers. The exact mass of potential biomarkers was searched in databases such as HMDB (http://www.hmdb.ca), METLIN (https://metlin.scripps.edu), and KEGG (http://www.genome.jp/kegg/) for biomarker identification. The identified biomarkers were introduced into metaboanalyst 4.0 (http://www.metaboanalyst.ca) for metabolic pathway analysis, and those whose critical value of metabolic pathway impact was greater than 0.01 were selected as a key potential metabolic pathway to integrate the metabolic pathway and carry out metabolic network analysis to find the core target of Chaenomeles Fructus intervention.

Statistical analysis was performed using SPSS 17.0 software, and the experimental data are expressed as the mean ± standard deviation (X ± SD). T tests were used to compare two groups, and the one-way analysis of variance (ANOVA) was used to compare differences between multiple groups. p < .05 was considered to indicate a significant difference.

3 RESULTS

3.1 Identification of chemical components in Chaenomeles Fructus

Chaenomeles Fructus samples were analyzed under the section “UPLC-Q-Exactive Orbitrap MS for Chemical Characterization” chromatographic and mass spectrometry conditions to obtain the UPLC-Q-Exactive orbitrap MS total ion current diagram of Chaenomeles Fructus, as shown in Figure 2. The results are shown in Table S1.

3.1.1 Amino acids

Compound 1 (Rt 0.66 min) yielded a [M + H]+ at m/z 175.11838, generating 116.07053 [M-CH2N3]+, 71.06892 [M-COOH-CH2N3]−, 70.06566 [M-CH2O2-CH2N3]−, and 60.05628 [M + H-NH3-COOH-C7H13]−, which was identified as arginine (Qu et al., 2008). Compound 4 (Rt 0.74 min) was identified as valine, showing main fragmentations at m/z 72.08121 [M-COOH]− and 58.01757 [M + H-COOH-NH3]− (Qu et al., 2008). Compound 5 showed [M + H]+ at m/z 182.08064 (C7H13NO2) with key fragmentations at m/z 165 and 119. It was identified as tyrosine (Zhang, Dong, et al., 2017). Compound 6 was leucine, which showed characteristic ions at m/z 86.09675 [M-COOH]+, 69.03406 [M-COOH-NH3]−, and 57.03419 [M + H-NH3-CH]+ (Cao et al., 2004; Qu et al., 2008).

3.1.2 Organic acids

In negative-ion mode, the retention time of organic acids is 0.71–33.34 min. Compound 8 (Rt 0.97 min) yielded a [M-H]− at m/z...
FIGURE 2 The total ion chromatogram of Chaenomeles Fructus extract was collected by mass spectrometry in positive and negative ion modes (a: Positive; B: Negative)

191.05516, producing 173.00809 [M-H-H\textsubscript{2}O\textsubscript{3}]\textsuperscript{−}, 85.02785 [M-H-C\textsubscript{3}H\textsubscript{5}O\textsubscript{3}]\textsuperscript{−}, which was identified as quinic acid (Wang et al., 2010). Compound 9 (Rt 1.03 min) yielded a [M-H]\textsuperscript{−} at m/z 117.01778, generating 99.00713 [M-H-H\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, 73.02792 [M-H-C\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, 55.01737 [M-H-H\textsubscript{2}O-C\textsubscript{O}2]\textsuperscript{−} and was confirmed with a standard and thus identified as succinic acid (Zhang, Dong, et al., 2017). Compound 11 was identified as gallic acid, showing [M-H]\textsuperscript{−} at m/z 153.01799, showing main fragmentations at m/z 191.05508 [M-H-C\textsubscript{6}H\textsubscript{4}O\textsubscript{6}]\textsuperscript{−}, 125.02288 [M-H-C\textsubscript{5}H\textsubscript{5}O\textsubscript{5}]\textsuperscript{−}, 81.49275 [M-H-C\textsubscript{4}O\textsubscript{4}]\textsuperscript{−}, which was identified as protocatechuic acid (Yu et al., 2016). Compound 14 was detected at 1.99 min with a calculated formula of C\textsubscript{7}H\textsubscript{12}O\textsubscript{5}, its characteristic fragments included ions at m/z 155.03384 [M-H-H\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, 137.02292 [M-H-C\textsubscript{6}H\textsubscript{4}O\textsubscript{5}]\textsuperscript{−}, 111.04358 [M-H-C\textsubscript{5}H\textsubscript{5}O\textsubscript{4}]\textsuperscript{−}, and 93.03295 [M-H-C\textsubscript{4}O\textsubscript{3}]\textsuperscript{−}, which were identical to those of shikimic acid. Compound 16 ([M-H]\textsuperscript{−}, m/z 137.02299) underwent successive loss of H\textsubscript{2}O (18 Da) and CO (28 Da) and was identified as 4-hydroxybenzoic acid (Gao et al., 1999). 2-isopropylmalic acid (17) eluting at 3.64 min showed an [M-H]\textsuperscript{−} ion at m/z 175.06000 (C\textsubscript{8}H\textsubscript{12}O\textsubscript{5}), which was identical to the reference standard. Compound 20 was identified as chlorogenic acid, showing main fragmentations at m/z 191.05508 [M-H-C\textsubscript{6}H\textsubscript{4}O\textsubscript{6}]\textsuperscript{−}, 173.04468 [M-H-C\textsubscript{5}H\textsubscript{5}O\textsubscript{5}]\textsuperscript{−}, and 161.02345 [M-H-C\textsubscript{4}O\textsubscript{4}]\textsuperscript{−} (Ju et al., 2007). Compound 21 was caffeic acid, which showed characteristic ions at m/z 135.04362 [M-H-C\textsubscript{2}O\textsubscript{2}]\textsuperscript{−} and 107.04925 [M-H-C\textsubscript{2}O\textsubscript{2}]\textsuperscript{−} (Yu et al., 2016). Compound 23 was identified as vanillic acid, producing the main fragmentations at m/z 153.01799 [M-H-C\textsubscript{6}H\textsubscript{4}O\textsubscript{6}]\textsuperscript{−}, 123.04520 [M-H-C\textsubscript{5}H\textsubscript{5}O\textsubscript{5}]\textsuperscript{−}, and 109.02951 [M-H-C\textsubscript{4}H\textsubscript{5}O\textsubscript{4}]\textsuperscript{−}. Compound 24 showed [M-H]\textsuperscript{−} at m/z 165.05443 (C\textsubscript{9}H\textsubscript{10}O\textsubscript{3}) with key fragment ions at m/z 148 and 71. It was identified as L-3-phenyl lactic acid. Compound 25 eluted at 11.07 min displayed [M-H]\textsuperscript{−} at m/z 367.10294, with main fragmentations at m/z 191.05502, 179.03419, 135.03912, and 93.03273. The fragment at m/z 191.05502 was due to the loss of C\textsubscript{6}H\textsubscript{3}O\textsubscript{3}, m/z 179.03419 was due to the loss of C\textsubscript{6}H\textsubscript{2}O\textsubscript{2}, and m/z 135.03912 and 93.03273 corresponded to C\textsubscript{6}H\textsubscript{2}O\textsubscript{2} and C\textsubscript{6}H\textsubscript{2}O, respectively. It was identified as methyl chlorogenate (Liu et al., 2016). Compound 40 was identified as linoleic acid, showing main fragmentations at m/z 263.23584 [M+H\textsubscript{2}O\textsubscript{2}]\textsuperscript{+}, 221.22533 [M-COOH-CH\textsubscript{2}]+, 179.14233 [M-COOH-C\textsubscript{2}H\textsubscript{4}]\textsuperscript{+}, and 165.12689 [M-COOH-C\textsubscript{2}H\textsubscript{4}]\textsuperscript{+} (Hou et al., 2015). Compound 46 (Rt 33.34 min) yielded a [M-H]\textsuperscript{−} at m/z 237.22162 [M-H-H\textsubscript{2}O\textsubscript{2}], 211.24319 [M-H-C\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, and 197.15478 [M-H-C\textsubscript{2}H\textsubscript{4}]\textsuperscript{−}, which was identified as palmitic acid. Other organic acids included 2 (tartaric acid), 3 (malic acid), 7 (citric acid), 10 (D-α-hydroxyglutaric acid), 12 (kojic acid), 15 (fumaric acid), 22 (benzoic acid), and 26 (cinnamic acid). The retention time, MS, and MS2 data of 2, 3, 7, 10, 12, 15, 23, and 28 were identical to the reference standards.

3.1.3 | Flavonoids

Compound 34 was identified as Luteolin, showing main fragmentations at m/z 243 [M-H-C\textsubscript{2}H\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, 241 [M-H-C\textsubscript{2}O\textsubscript{2}]\textsuperscript{−}, 199 [M-H-C\textsubscript{6}H\textsubscript{2}O-C\textsubscript{O}2]\textsuperscript{−}, 217 [M-H-C\textsubscript{6}H\textsubscript{2}O-C\textsubscript{O}2]\textsuperscript{−}, and 175 [M-H-C\textsubscript{6}H\textsubscript{2}O-C\textsubscript{O}2]\textsuperscript{−}. Compound 27 eluted at 14.26 min and displayed [M-H]\textsuperscript{−} at m/z 577.15628, with main fragmentations at m/z 413.08788 and 297.04053. The fragment at m/z 413.08788 was due to the loss of C\textsubscript{6}H\textsubscript{2}O\textsubscript{2} and the fragment at m/z 297.04053 was due to the loss of C\textsubscript{6}H\textsubscript{2}O\textsubscript{2} and C\textsubscript{6}H\textsubscript{2}O\textsubscript{2}. It was identified as vitexin-2-O-rhamnoside. Compounds 28, 29, 31, and 35 displayed molecular ions at m/z 609.14611, 463.08820, 433.07763, and 447.09328, respectively, which produced a common fragment at m/z 301. The losses of 308, 162, 132, and 146 Da corresponded to residues of rutinose, galactose, arabinose, and rhamnose, respectively. Compounds 28, 29, 31, and 35 were thus identified as
rutin (kaempferol-3-O-rutinoside), hyperoside (quercetin-3-O-galactoside), quercetin-3-O-arabinofuranoside, and quercitrin (kaempferol-3-O-rhamnopyranoside), respectively. Compound 37 ([M-H]-, m/z 271.06131) underwent successive losses of C\(_{6}\)H\(_{5}\)O\(_{4}\) (164 Da), C\(_{6}\)H\(_{4}\)O\(_{2}\) (120 Da), and C\(_{6}\)H\(_{2}\)O\(_{2}\) (94 Da) and was identified as naringenin (Sun et al., 2020). Compound 33 showed an m/z [M-H]− at 433.11414 (C\(_{21}\)H\(_{22}\)O\(_{10}\)). The key fragment of m/z 271.06131 indicates that there is a glucose group in the structure. Compound 33, having similar fragmentations to 37, was identified as naringenin-7-O-glucoside. Compound 38 (Rt 18.16 min) yielded a [M-H]+ at m/z 257.04504 [M-H-CO]−, 229.0528 [M-H-2CO]−, 185.05972 [M-H-2CO-CO]−, and 151.00232 [M-H-C\(_{4}\)H\(_{6}\)O\(_{2}\)]−, which was identified as kaempferol (Bai et al., 2018). Other flavonoids included 18 (catechin), 30 (vitexin), 32 (vicenin), 33, and 36 (quercetin). The retention time, MS, and MS2 data of 18, 32, 34, and 37 were identical to the reference standards.

### 3.1.4 | Triterpenoids

A total of seven triterpenoids (39, 41, 42, 43, 44, 45, 47, and 48) were found in Chaenomeles Fructus. Compound 39 was detected at 21.93 min with a calculated formula of C\(_{30}\)H\(_{48}\)O\(_{6}\). Its characteristic fragments included ions at m/z 453.34192 [M-H-HCO]− and 407.33151 [M-H-C\(_{4}\)H\(_{6}\)O-CO]−, which were identical to those of maslinic acid (Wang et al., 2017). Compound 41 was identified as 3-O-acetyl pomolic acid, showing main fragmentations at m/z 495.35403 [M-H-H\(_{2}\)O]− and 453.14035 [M-H-H\(_{2}\)O-C\(_{2}\)H\(_{2}\)O]−. Compound 42 showed [M + H]+ at m/z 457.36600 (C\(_{30}\)H\(_{48}\)O\(_{3}\)) with key fragment ions at m/z 439, 411, and 397. It was identified as betulinic acid. Compound 43 (Rt 29.46 min) yielded a [M + H]+ at m/z 439.35739 [M-H-H\(_{2}\)O]−, 411.36209 [M + H-H\(_{2}\)O-CO]−, and 249.18672 [M + H-C\(_{14}\)H\(_{24}\)O\(_{4}\)]−, which was identified as oleanolic acid (Wang et al., 2017). Compound 44 was betulin, which showed characteristic ions at m/z 425.37711 [M + H-H\(_{2}\)O]−, 407.29532 [M + H-2H\(_{2}\)O]−, and 221.19011 [M + H-C\(_{15}\)H\(_{26}\)O]− (Huo et al., 2016). Compound 45 (Rt 31.98 min) yielded a [M + H]+ at m/z 425.37622 [M + H-H\(_{2}\)O]− and 395.36612 [M + H-H\(_{2}\)O-CH\(_{2}\)O]−, which was identified as erythrodiol. Compound 47 (M + H)+, m/z 427.39383; C\(_{30}\)H\(_{48}\)O\(_{3}\) had key fragments at m/z 409, 260, and 191. They were identified as y-aminor. Ursolic acid (48) eluting at 34.55 min showed a [M-H]− at m/z 455.35269 (C\(_{30}\)H\(_{48}\)O\(_{3}\)), which was identical to the reference standard.

### 3.1.5 | Others

Escinolide (19) eluting at 4.77 min showed a [M-H]+ at m/z 177.01933 (C\(_{8}\)H\(_{10}\)O\(_{3}\)), which was identical to the reference standard.

### 3.2 | Network construction

Using the 48 identified compounds to find their targets in TC MSP and Swiss TargetPrediction, a total of 316 targets were obtained and named according to their gene symbols, and a total of 7 compounds were screened (Table 1). We used "rheumatoid arthritis" as the search term to construct related targets of RA in the TTD and OMIM databases and then merged the gene targets retrieved from the two databases, removed duplicate values, and took their union. A total of 368 related genes were identified. The Venny 2.1.0 tool (https://bioinfogp.cnb.csic.es/tools/venny/) was used to map and compare the target genes of Chaenomeles Fructus with the RA genes to obtain the intersection of 77 target genes (Figure 3a). Then, they were imported into the STRING database and Cytoscape 3.7.1 to construct a PPI network to obtain protein interaction relationships (Figure 3b).

The result of the screening degree score greater than 21 shows that there are 25 nodes and 238 edges in the network, and TNF, IL6, IL1B, VEGFA, MAPK3, etc., are its main targets. GO function annotation includes three aspects: cell component, molecular function, and biological process. Cell components mainly involved the side of the membrane, apical part of the cell, and secretory granule lumen; molecular function was mainly coupled with oxidoreductase activity, monocarboxylic acid binding, and cytokine receptor binding; and the biological process mainly involved the i-cosanoid metabolic process, steroid metabolic process, response to lipopolysaccharide, and regulation of inflammatory response. (Figure 3c). The top 20 significantly enriched pathways are shown in Figure 3d. Among these potential pathways, the AGE-RAGE signaling pathway, cAMP signaling pathway, CAMP signaling pathway, HIF-1 signaling pathway, and arachidonic acid metabolism were also included, which were categorized as related to inflammation. After integrating drug target prediction, pathway and function enrichment, and network analyses, we identified TNF, IL6, IL1B, VEGFA, and MAPK3 as relatively highly relevant targets in inflammation. Additionally, they are considered the key targets of Chaenomeles Fructus in the treatment of RA. Thus, we speculated that Chaenomeles Fructus may interfere with inflammation.
by inhibiting the release of inflammatory factors and inflammatory signaling pathways to treat RA.

3.3 | Experimental validation

3.3.1 | CFA-injected rats

During the experiment, it was observed that the rats were easy to move, and the sizes of the left and right feet were similar before modeling. After modeling for 4 h, the rats developed swelling of the right toe and limited movement, especially the arthritic symptoms of the right foot, which indicated that the model was successful. There was no significant change in the volume of the toes of the rats in the control group, and the rats were active. The swelling of the right foot of the rats in each dose group of Chaenomeles Fructus and TG group was significantly relieved after administration (Figure 4). Compared with the model group, the swelling degree of the rat toes in the high- and medium-dose groups was significantly reduced after 21 days.

3.3.2 | Multivariate statistical analysis of metabolomics data

All quality control (QC) samples were pooled together and concentrated at a 95% confidence interval, which indicates that the instrument is working properly and that the data quality is reliable. The metabolites were discovered with significant differences between the groups shown by PCA (Figure 5a), PLS-DA (Figure 5b), and S-plot (Figure 5C). The results of the PLS-DA model showed an obvious separation trend among all groups; the samples of each group were separated from each other and clustered together individually. The model group and the control group were separated clearly, which indicated that the animal model was successful, and the occurrence of disease could cause significant changes in endogenous metabolites.
100 permutation tests (Figure 5d) were used to verify the accuracy of the model.

3.3.3 | Potential biomarkers

Through the constructed PLS-DA model, the metabolic ions that deeply influenced the clustering trend were selected. Metabolites of VIP value >1 were selected. Verification was performed on variables selected by testing two independent-samples T. Differential metabolite data were evaluated as significant at \( p < .05 \) based on the Compound Discoverer 2.0 software database, and MZ Cloud, ChemSpider, Variable discrepancy identification was achieved by adapting high-resolution MS spectra and MS/MS spectra combined with secondary fragmentations. The metabolite discrepancy data achieved in the verification were analyzed through MetaboAnalyst 3.0 for enrichment analysis. Referring to relevant literature reports, related metabolic pathways involved in discrepant metabolites were analyzed by using the KEGG online database. Enrichment analysis and analysis of the relevant metabolic pathways involved in differential metabolites using the KEGG online database and related. The results are shown in Table S2.

3.3.4 | Metabolic pathway analysis

The differentially produced metabolites were entered into Metaboanalyst (http://www.metaboanalyst.ca) for enrichment analysis of the metabolic pathways. Metabolic pathway analysis found that Chaenomeles Fructus mainly interferes with arachidonic acid metabolism, nicotinate and nicotinamide metabolism, tryptophan metabolism, and branched-chain amino acid catabolism (valine, leucine, and isoleucine degradation) (Figure 6).

3.3.5 | Effect of Chaenomeles Fructus alcohol extract on the protein expression of ERK, JNK, P-ERK, and P-JNK in the synovium of RA model rats

The protein expression results are shown in Figure 7 and Table 2. The expression of ERK, JNK, P-ERK, and P-JNK proteins related to inflammation increased, but their expression levels showed significant differences compared with the control group (\( p < 0.01 \)). After the intervention, the expression levels of ERK, JNK, and P-JNK decreased, which were significantly different from the model group (\( p < 0.01 \)).

4 | DISCUSSION

In recent years, the application of liquid-mass spectrometry technology in the identification of multicomponent medicinal plants and their compound ingredients has become increasingly extensive (Li et al., 2018; Liu et al., 2017; Yin et al., 2020), but research on the medicinal plant Chaenomeles Fructus mainly uses gas-mass spectrometry to analyze the volatile oil of Chaenomeles Fructus (Wang, Zhang, et al., 2020; Zhang, Jiang, et al., 2017), while the liquid-mass spectrometry analysis of the nonvolatile oil components of Chaenomeles Fructus is less common. This study used UPLC-Q-Exactive orbitrap MS technology to identify the chemical components of 48 Chaenomeles Fructus, including four types: amino acids, organic acids, flavonoids, and triterpenes.

The common animal models of RA mainly include adjuvant-induced arthritis (AA), collagen II-induced arthritis (CIA), streptococcal cell wall-induced arthritis (SCW), and pristane-induced arthritis (PIA). The AA model is more in line with the economic principle, the construction method of the model is relatively simple, and the success rate of modeling is high (Li, Li, & Li, 2021; Li, Zhang, et al., 2021). The CIA modeling process is cumbersome, and the preparation of the immune mixture requires the entire operation on ice (Li, Li, & Li, 2021). The economic cost of SCW model inducers is relatively high, and the intra-articular injection technique is difficult. The peptidoglycan-polysaccharide (PG-PS) structure of the different Streptococcus cell walls and the degree of development of the SCW are also different, which leads to the frequency of use of the SCW model in the study being low (Cromartie et al., 1977; Marijnissen et al., 2014). The course of PIA is less invasive, but the construction of the model is time-consuming (Hutamakul et al., 2009; Song et al., 2015). In this study, the CFA-induced AA model was used to investigate the therapeutic effect of Chaenomeles Fructus alcohol extract on RA. An immune agent, CFA, is used to stimulate the animal model to form immune hyperactive joint inflammation. The pathological changes were very similar to those of RA in clinical practice (Chen et al., 2019; Honmore et al., 2019; Tang et al., 2021; Zhu, 2016). Paw swelling is a typical symptom of arthritic rats and is measured to determine the anti-inflammatory activity of various drugs. Our results showed that the high-, medium-, and low-dose Chaenomeles Fructus alcohol extracts reduced toe swelling in CFA-induced AA model rats to varying degrees.
It indicates that the alcohol extract of *Chaenomeles Fructus* has a good anti-inflammatory effect and has a definite therapeutic effect on the treatment of RA.

The results of the PPI network revealed that the core targets of *Chaenomeles Fructus* in the treatment of RA are TNF, IL6, IL1B, VEGFA, MAPK3, etc. TNF, IL-6, and IL-1B, as proinflammatory cytokines, can stimulate the inflammation and degradation of bone and cartilage and gradually lead to arthritis damage and deformity in RA patients and finally disability (Luo et al., 2022). VEGF can significantly improve the permeability of blood vessels in patients, can promote the formation and development of inflammation,
and is of great significance to the formation of chronic inflammation. The serum VEGF level is an important indicator for judging the condition and prognosis of RA (Yu et al., 2018). MAPK3, known as ERK1, is involved in many pathogenic processes of RA, including its role in promoting the expression of inflammatory cytokines (Bauer et al., 2000). Combined with GO function and KEGG pathway enrichment analysis, the intersection target mainly involves the AGE-RAGE signaling pathway, cAMP signaling pathway, HIF-1 signaling pathway, arachidonic acid metabolism, and other inflammatory response regulation pathways. Studies have shown that AGE-RAGE can stimulate the production of proinflammatory factors. It can also act as an inflammatory factor to activate innate immune cells and further lead to the development of arthritis (Millerand et al., 2019). As an important second messenger in cells, cAMP's main role is to bind to PKA regulatory subunits, thereby activating PKA. The increase in the content of cAMP and the activation of PKA eventually cause the activation of NF-κB and the increase in the expression of the proinflammatory cytokine IL-6, which are thought to be associated with RA disease progression (Illovskova & Barrow, 2021; Narasimamurthy et al., 2012; Wu et al., 2013). HIF-1α is a very important transcriptional regulator in the mammalian body under hypoxic conditions. Studies have shown that NF-κB can promote the secretion of inflammatory factors by macrophages in a HIF-1α-dependent and HIF-1α-independent manner, thereby inducing the occurrence of RA (Knowles et al., 2006). The arachidonic acid (AA) metabolic pathway is an important metabolic pathway in the inflammatory response and is highly activated in the inflammatory response. When cells are stimulated, the cell membrane phospholipase A2 (PLA2) releases AA (Yu et al., 2022). The metabolite of arachidonic acid, prostaglandin E2 (PGE2), is a major mediator of inflammation in diseases such as rheumatoid arthritis and osteoarthritis (Park et al., 2006). It can be seen that Chaenomeles Fructus mainly alleviates RA from an anti-inflammatory perspective.

There are many signaling pathways involved in inflammation, and the inhibition of the MAPK signaling pathway is an important means to effectively control the occurrence of inflammation. MAPK mainly includes three major pathways: JNK, ERK1/2, and p38. JNK can be activated by inflammatory factors such as TNFα and IL-1β. ERK1/2 can promote the expression of inflammatory cytokines, and p38 can promote the expression and secretion of inflammatory factors in cells (Bauer et al., 2000; Luo et al., 2022). In this study, the alcohol extract of Chaenomeles Fructus reduced the protein expression of JNK and ERK1/2 protein in the synovium of the knee joint of RA rats, suggesting that the alcohol extract of Chaenomeles Fructus can inhibit the MAPK signaling pathway, thus reducing the release of inflammatory factors and inhibiting the abnormal proliferation of the synovial membrane to inhibit joint bone erosion in RA.

Based on the metabolomics research method, this experiment constructed the overall metabolic network of Chaenomeles Fructus intervention for RA by integrating the body's metabolic pathways. Chaenomeles Fructus interferes with the metabolism of inflammatory factors by downregulating arachidonic acid metabolism and branched-chain amino acid catabolism, thereby inhibiting the production of inflammatory factors and reducing the inflammatory response. Arachidonic acid is a long-chain polyunsaturated fatty acid and an important mediator that regulates inflammation (Higgins & Lees, 1984; Sala et al., 2018). It is involved in the metabolism of arachidonic acid and the synthesis and release of inflammatory factors such as tumor factors and interleukins (Lewis et al., 1990). BCAAs include leucine, isoleucine, and valine. Supplementation with BCAAs could activate mTORC1 and upregulate the NF-κB signaling pathway, increasing the release of proinflammatory cytokines in human peripheral blood mononuclear cells and endothelial cells (Ye et al., 2020; Zhenyukh et al., 2017, 2018). In the model group of this study, the content of arachidonic acid and BCAAs in the serum was upregulated, suggesting that there is an inflammatory reaction in the serum of RA rats. After administration of Chaenomeles Fructus alcohol extract, the contents of arachidonic acid and BCAAs were decreased, indicating that Chaenomeles Fructus could interfere with the metabolism of arachidonic acid and BCAAs in RA rats, thus affecting the inflammatory reaction in which arachidonic acid and BCAAs were involved and producing anti-inflammatory effects.

The integrated network pharmacology results showed that Chaenomeles Fructus mainly relieves RA by interfering with the MAPK signaling pathway, AGE-RAGE signaling pathway, cAMP signaling pathway, HIF-1 signaling pathway, arachidonic acid metabolism, and branched-chain amino acid catabolism, thereby inhibiting the production of inflammatory factors and reducing the inflammatory response. Arachidonic acid is a long-chain polyunsaturated fatty acid and an important mediator that regulates inflammation (Higgins & Lees, 1984; Sala et al., 2018). It is involved in the metabolism of arachidonic acid and the synthesis and release of inflammatory factors such as tumor factors and interleukins (Lewis et al., 1990). BCAAs include leucine, isoleucine, and valine. Supplementation with BCAAs could activate mTORC1 and upregulate the NF-κB signaling pathway, increasing the release of proinflammatory cytokines in human peripheral blood mononuclear cells and endothelial cells (Ye et al., 2020; Zhenyukh et al., 2017, 2018). In the model group of this study, the content of arachidonic acid and BCAAs in the serum was upregulated, suggesting that there is an inflammatory reaction in the serum of RA rats. After administration of Chaenomeles Fructus alcohol extract, the contents of arachidonic acid and BCAAs were decreased, indicating that Chaenomeles Fructus could interfere with the metabolism of arachidonic acid and BCAAs in RA rats, thus affecting the inflammatory reaction in which arachidonic acid and BCAAs were involved and producing anti-inflammatory effects.

| Groups | ERK  | P-ERK | JNK  | P-JNK |
|--------|------|-------|------|-------|
| Control| 0.29 ± 0.02 | 0.13 ± 0.01 | 0.22 ± 0.05 | 0.12 ± 0.01 |
| Model  | 0.78 ± 0.04** | 0.28 ± 0.01** | 0.63 ± 0.09** | 0.34 ± 0.07** |
| Low    | 0.45 ± 0.05 | 0.26 ± 0.02 | 0.60 ± 0.12 | 0.29 ± 0.05 |
| Medium | 0.34 ± 0.09**Δ△ | 0.34 ± 0.09**Δ△ | 0.41 ± 0.04Δ△ | 0.22 ± 0.05**Δ△ |
| High   | 0.31 ± 0.01**Δ△ | 0.31 ± 0.01**Δ△ | 0.26 ± 0.02Δ△ | 0.16 ± 0.02**Δ△ |
| TG     | 0.31 ± 0.02**Δ△ | 0.31 ± 0.02**Δ△ | 0.25 ± 0.06Δ△ | 0.13 ± 0.03**Δ△ |

Note: (*p < .05, vs. group Control; **p < .01, vs. group Model).
metabolism, and other inflammatory pathways. Inflammation plays an important role in the pathological process of RA. Then, we used CFA-induced RA rats to carry out the verification test. Combining MAPK signaling pathway proteins and serum nontargeted metabolomics results, it was concluded that *Chaenomeles Fructus* mainly interferes with the metabolism of inflammatory factors through arachidonic acid metabolism, the MAPK signaling pathway, and branched-chain amino acid catabolism to inhibit the production of inflammatory factors and reduce the inflammatory response. In summary, the results of the network pharmacology prediction and the verification experimental results were analyzed by Venn analysis, and the experimental results were concluded; that is, *Chaenomeles Fructus* mainly interferes with the inflammation of RA by inhibiting arachidonic acid metabolism and the MAPK signaling pathway (Figure 8).

## CONCLUSION

Taking all the above results together, we identified 48 chemical components from *Chaenomeles Fructus* based on UPLC-Q-Exactive orbitrap MS, which mainly includes four types: amino acids, organic acids, flavonoids, and triterpenes. Moreover, we predicted the mechanism of action of *Chaenomeles Fructus* in the treatment of RA with network pharmacology and verified it through CFA-induced RA in rats. The results of the network pharmacology prediction and the verification experimental results were analyzed by Venn analysis, and the experimental results concluded that *Chaenomeles Fructus* mainly interferes with the inflammation of RA by inhibiting arachidonic acid metabolism and the MAPK signaling pathway.

## ACKNOWLEDGMENTS

This study was supported by the foundation of the Youth Innovation and technology program for the universities of Shandong Province (2019KJM005), Key Technology Research and Development Program of Shandong Province (2018CXGC1308), and University Science and technology program of Shandong Province (No. J17KZ004).

## CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

## ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All animal welfare and experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the protocols used were approved by the Animal Ethics Committee of Shandong University of Traditional Chinese Medicine Laboratory Animal Center, Jinan, China.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## ORCID

Haiqiang Jiang https://orcid.org/0000-0002-1294-4370

## REFERENCES

Bai, H. Y., Liu, B. Z., & Huo, J. H. (2018). Analysis of flavonoids in wild chrysanthemum based on liquid mass spectrometry technology. *China Journal of Traditional Chinese Medicine Science and Technology*, 25, 826–830.

Bauer, G. J., Arbabi, S., Garcia, I. A., de Hingh, I., Rosengart, M. R., & Maier, R. V. (2000). Adherence regulates macrophage signal transduction and primes tumor necrosis factor production. *Shock*, 14, 435–440. https://doi.org/10.1097/00024382-200014040-00003

Cao, S. X., Yang, X. L., Chen, X. L., Liao, X. C., & Zhao, Y. F. (2004). Study on electrospray mass spectrometry of amino acid complexes. *Journal of Instrumental Analysis*, 23, 64–66.

Chen, Z., Bozec, A., Ramming, A., & Schett, G. (2019). Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. *Nature Reviews Rheumatology*, 15, 9–17. https://doi.org/10.1038/s41584-018-0109-2

Chen, Y., Wang, Y., Liu, M., Zhou, B., & Yang, G. (2020). Diosmetin exhibits anti-proliferative and anti-inflammatory effects on TNF-alpha-stimulated human rheumatoid arthritis fibroblast-like synovocytes through regulating the Akt and NF-kappaB signaling pathways. *Phytotherapy Research*, 34, 1310–1319. https://doi.org/10.1002/ptr.6596

Cojocaru, M., Cojocaru, I. M., Silosi, I., Vrabie, C. D., & Tanasescu, R. (2010). Extra-articular manifestations in rheumatoid arthritis. *Maedica*, 5, 286–291.
Cromartie, W. J., Craddock, J. G., Schwab, J. H., Anderle, S. K., & Yang, C. H. (1977). Arthritis in rats after systemic injection of streptococcal cells or cell walls. The Journal of Experimental Medicine, 146, 1585–1602. https://doi.org/10.1084/jem.146.6.1585

Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Research, 47, W357–W364. https://doi.org/10.1093/ngr/kxz382

Gao, X. M. (2007). Chinese materia medica. China Press of Traditional Chinese Medicine.

Gao, C. W., Wang, Y., Lei, Z. M., Duan, Z. H., & Li, L. (1999). Research on organic acids in wrinkled papaya. Journal of Yunnan University: Natural Science Edition, 4, 319–321.

Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A., & McKusick, V. A. (2005). Online mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Research, 33, D514–D517. https://doi.org/10.1093/nkj/di033

Higgins, A. J., & Lees, P. (1984). The acute inflammatory process, arachidonic acid metabolism and the mode of action of anti-inflammatory drugs. Equine Veterinary Journal, 16, 163–175. https://doi.org/10.1111/j.2042-3306.1984.tb01893.x

Honmore, V. S., Kandhare, A. D., Kadam, P. P., Khedkar, V. M., Natu, A. D., Rojatkar, S. R., & Bodhanakar, S. L. (2019). Diarylheptanoid, a constituent isolated from methanol extract of Alpinia officinarum attenuates TNF-α level in Freund’s complete adjuvant-induced arthritis in rats. Journal of Ethnopharmacology, 229, 233–245. https://doi.org/10.1016/j.jep.2018.10.019

Hou, L. B. (2011). Observation on the curative effect of viper Chaenomeles fructus capsule in the treatment of rheumatoid arthritis. Chinese Journal of Clinical Rational Drug Use, 21, 35–36. https://doi.org/10.15888/cjcrdu.2011.21.014

Hou, Y., Ma, Y., Zou, L. S., Liu, X., Liu, X. H., Luo, Y. Y., Liu, J. X., Lan, C. W., & Yuan, J. D. (2015). UPLC-triple TOF-MS/MS analysis of the dynamic changes of the accumulation of the metabolites of Taizishen produced in Fujian. Chinese Journal of New Drugs, 24, 90–96. https://doi.org/10.13836/j.issn:1000-0306.2015.15.04

Hu, H., Shi, X., & Chen, J. (2021). Application effect of Ma Qianzi Chaenomeles fructus pills in patients with rheumatoid arthritis. Chinese Folk Therapy, 29, 50–52. https://doi.org/10.19621/j.cnki.31-3555/s.2021.2020

Huo, J. H., Du, X. W., Sun, G. D., Zhang, H. Y., & Wang, W. M. (2016). Analysis of the composition of Beiqinglongyi based on UPLC-Q-TOF/MS. Chinese Traditional and Herbal Drugs, 47, 3379–3388.

Hutamekalin, P., Saito, T., Yamaki, K., Mizutani, N., Brand, D. D., Waritani, H., J., Du, X. W., Sun, G. D., Zhang, H. Y., & Wang, W. M. (2016). Analysis of the composition of Beiqinglongyi based on UPLC-Q-TOF/MS. Acta Pharmacutica Sinica, 42, 1074–1077. https://doi.org/10.16438/j.0513-4870.2007.10.008

Knowles, H. J., Mole, D. R., Ratcliffe, P. J., & Harris, A. L. (2006). Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: Effect of natural resistance-associated macrophage protein 1. Cancer Research, 66(5), 2600–2607. https://doi.org/10.1158/0008-5472

Kuwana, M., Nakagawa, S., Nakaiashi, M., Hashimoto, M., Ito, H., Yamamoto, W., Nakashima, R., Tanaka, M., Fujii, T., Omura, T., Imai, S., Nakagawa, T., Yonezawa, A., Imai, H., Mimori, T., & Matsubara, K. (2018). Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis. PLoS One, 13, e0206943. https://doi.org/10.1371/journal.pone.0206943

Lewis, R. A., Austen, K. F., & Soberman, R. J. (1990). Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. The New England Journal of Medicine, 323, 645–655. https://doi.org/10.1056/NEJM199009063231006

Li, A. M., Li, X. J., & Li, R. S. (2021). Research progress of rheumatoid arthritis rat and mouse model. Chinese Journal of Comparative Medicine, 1, 151–156.

Li, Z., Liu, J., Zhang, D., Du, X., Han, L., Lv, C., Li, Y., Wang, R., Wang, B., & Huang, Y. (2018). Nuciferine and paoniflorin can be quality markers of Tangzhiguo tablet, a Chinese traditional patent medicine, based on the qualitative, quantitative and dose-exposure-response analysis. Phytomedicine, 44, 155–163. https://doi.org/10.1016/j.phymed.2018.02.006

Li, Y., Wu, C. F., Chen, B. L., & Zhu, Y. P. (2020). Significance of compatibility of Chinese medicine taking “hubarb-Copts Rhizoma” chinses as an example based on system pharmacology. Chinese Archives of Traditional Chinese Medicine, 38, 154–157 +277–278. https://doi.org/10.13193/j.cn1673-1673.2020.02.038

Li, Q., Zhang, F., Peng, F. Z., Luo, Q. Y., Li, X. J., & Liu, L. (2021). Research progress on experimental animal models of rheumatoid arthritis. Chinese Pharmacological Bulletin, 37, 1492–1497.

Liu, J. X., Luo, Y. Y., Liu, X. H., Song, J. P., Hua, Y. J., Wang, S. N., Zhao, H., & Yan, Y. (2016). Based on UPLC-triple TOF-MS/MS technology to analyze the different chemical constituents of xanthum and xanthim. Chinese Traditional and Herbal Drugs, 47, 3951–3958.

Liu, J., Zhang, Y., Hao, Y., Zhao, Y., Li, Y., Qin, R., Lv, C., & Lu, J. (2017). Chemical composition differentiation of Shen-Shuai-Ning granule between combined decoction and separated decoction using HPLC-DAD-ESI-QTOF-MS. Biomedical Chromatography, 31(9), e4398. https://doi.org/10.1002/bmc.4398

Luo, S., Li, X. F., Huang, C., Qin, C. S., & Li, J. (2022). Research progress of inflammatory factors in rheumatoid arthritis. Chinese Pharmacological Bulletin, 3, 330–338.

Marjinnsen, R. J., Roeleveld, D. M., Young, D., Nickerson-Nutter, C., Abdollahi-Roodsaz, S., Garcia de Aquino, S., van de Loo, F. A., van Spriel, A. B., Boots, A. M., van den Berg, W. B., & Koenders, M. I. (2014). Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis. Arthritis & Rheumatology, 66, 886–895. https://doi.org/10.1002/art.38312

Milverand, M., Berenbaum, F., & Jacques, C. (2019). Danger signals and inflamming in osteoarthritis. Clinical and Experimental Rheumatology, 120(5), 48–56.

Narasimamurthy, R., Hatori, M., Nayak, S. K., Liu, F., Panda, S., & Verma, I. M. (2012). Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proceedings of the National Academy of Sciences of the United States of America, 109(31), 12662–12667. https://doi.org/10.1073/pnas.1209965109

Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006). Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. Clinical Immunology, 119, 229–240. https://doi.org/10.1016/j.clim.2006.01.016
biologist-oriented resource for the analysis of systems-level data-sets. *Nature Communications*, 10, 1523. https://doi.org/10.1038/s41467-019-09234-6

Zhu, Y. F. (2016). *Comparison of 4 kinds of Wistar rats animal model of rheumatoid arthritis*. University of Science and Technology.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Sun, M., Zhao, H., Liu, Y., Ma, Y., Tian, Z., Wang, H., Wei, S., Guo, Q., Gu, Z., & Jiang, H. (2022). Deciphering the pharmacological mechanisms of *Chaenomeles Fructus* against rheumatoid arthritis by integrating network pharmacology and experimental validation. *Food Science & Nutrition*, 10, 3380–3394. https://doi.org/10.1002/fsn3.2938